What will be the price list of serpotinib/serpatinib in 2025?

Selpercatinib As RET target inhibitor, it plays an important role in the era of precision medicine. Its indications cover RET fusion-positive non-small cell lung cancer ( NSCLC) , RET fusion thyroid cancer and RET mutant medullary thyroid cancer. It is one of the first RET-specific targeted drugs to be acceleratedly approved by the FDA and EMA. Due to the low proportion of RET fusion-driven cancers in the overall tumor population, there was a lack of effective treatments in the past, and the emergence of seputinib has significantly changed the treatment landscape for these patients.

Multiple studies have shown that the drug can bring about a longer disease control period in people with lung cancer and thyroid cancer, and also shows strong efficacy in patients with central nervous system metastasis, which makes it gradually become the preferred choice for RET-positive patients in clinical practice.

As for price, the original research price of Septinib in the European and American markets is relatively high. Taking the United States as an example, public information shows that the cost of treatment with this drug is approximately between 20,000 and 100,000 yuan (the price may fluctuate due to exchange rates). Since the drug is a long-term medication, the overall economic burden can be imagined. After entering the Chinese market, the price has dropped significantly, and some regions have included it in the medical insurance negotiation catalog, which has greatly reduced the actual out-of-pocket payment ratio of patients.

There are also large price differences in different countries and regions. For example, generic drugs may appear in India and other places, and their prices are usually much lower than the original drugs. However, the efficacy and quality need to be comprehensively evaluated based on supervision and actual clinical use.

Overall, the application value of seputinib has been widely recognized in clinical practice around the world, and the price issue may be further optimized in the future with the development of medical insurance policies, international negotiations and the launch of generic drugs. For patients, choosing such highly targeted precision drugs requires not only focusing on efficacy, but also considering their own financial affordability, medical insurance coverage, and the doctor's treatment plan.

Reference:https://en.wikipedia.org/wiki/Selpercatinib